Lexicon Pharmaceuticals Inc. (LXRX)

6.25
0.21 3.48
NASDAQ : Health Technology
Prev Close 6.04
Open 6.08
Day Low/High 6.01 / 6.27
52 Wk Low/High 4.25 / 13.97
Volume 267.28K
Avg Volume 625.00K
Exchange NASDAQ
Shares Outstanding 106.27M
Market Cap 627.00M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Lexicon Pharmaceuticals (LXRX) Is Today's Strong On High Volume Stock

Lexicon Pharmaceuticals (LXRX) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a strong on high relative volume candidate

Trade-Ideas: Lexicon Pharmaceuticals (LXRX) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Lexicon Pharmaceuticals (LXRX) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial

Lexicon Shares Soar After Success in Late-Stage Cancer Drug Trial

Shares of Lexicon Pharmaceuticals are up nearly 50% since the company announced Monday that its cancer drug telotristat etiprate met its primary goal in a late-stage clinical trial.

Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade

Lexicon CEO: Carcinoid Drug Offers Biggest Advance in Over a Decade

Lexicon Pharmaceuticals (LXRX) shares are up nearly 50% since it announced Monday that its carcinoid syndrome drug telotristat etiprate met its primary endpoint in a late stage clinical trial.

Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal

Stock To Watch: Lexicon Pharmaceuticals (LXRX) In Perilous Reversal

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a "perilous reversal" (up big yesterday but down big today) candidate

Market Wrap: Stocks Fall With Price of Oil

Energy and materials names lead the losers.

Today's Pre-Market Mover With Heavy Volume: Lexicon Pharmaceuticals (LXRX)

Today's Pre-Market Mover With Heavy Volume: Lexicon Pharmaceuticals (LXRX)

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a pre-market mover with heavy volume candidate

Weak On High Volume: Lexicon Pharmaceuticals (LXRX)

Weak On High Volume: Lexicon Pharmaceuticals (LXRX)

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate

Lexicon Pharmaceuticals (LXRX) Strong On High Relative Volume Today

Lexicon Pharmaceuticals (LXRX) Strong On High Relative Volume Today

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a strong on high relative volume candidate

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Lexicon Pharmaceuticals (LXRX) Weak On High Volume Today

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate

Today's Weak On High Volume Stock: Lexicon Pharmaceuticals (LXRX)

Today's Weak On High Volume Stock: Lexicon Pharmaceuticals (LXRX)

Trade-Ideas LLC identified Lexicon Pharmaceuticals (LXRX) as a weak on high relative volume candidate

Lexicon Pharmaceuticals Larger Than S&P 500 Component Tenet Healthcare

Lexicon Pharmaceuticals Larger Than S&P 500 Component Tenet Healthcare

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Lexicon Pharmaceuticals, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tenet Healthcare Corp.

4 Stocks Under $10 Triggering Breakout Trades

4 Stocks Under $10 Triggering Breakout Trades

These under-$10 stocks are within range of triggering breakout trades.

Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate

Lexicon And Ipsen Enter Into Ex-North America/Japan Licensing And Commercialization Agreement For Telotristat Etiprate

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Lexicon Pharmaceuticals, Inc.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The Billion-Dollar Biotech Club: Speculation Trumped Risk

The list of biotech and drug stocks with billion-dollar market values almost doubled in 2013 -- a sign that investors loved speculation and were rewarded for it.

Lexicon Pharma's Never-Ending Diabetes Drug Partner Talks

Lexicon Pharma's Never-Ending Diabetes Drug Partner Talks

Lexicon CEO Arthur Sands has been promising a diabetes partnership for two years.

Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership

Lexicon Pharma Falls on Concerns Raised by Merck-Pfizer Diabetes Partnership

Lexicon needs a partner for its diabetes drug, but Merck chose Pfizer. Is Lexicon having trouble finding a partner of its own?

8 Stocks Under $5 Seeing Institutional And Insider Buying

8 Stocks Under $5 Seeing Institutional And Insider Buying

Here we present a list of eight stocks trading under $5 that have seen net institutional and insider buying over [...]

7 Biotechnology Stocks With Insider Buying Activity

7 Biotechnology Stocks With Insider Buying Activity

Biotech stocks can provide sudden and magnificent returns, but they can be just as unforgiving. How can you decide which [...]

10 Stocks Insiders And Hedge Funds Think Will Go Higher

10 Stocks Insiders And Hedge Funds Think Will Go Higher

One way to pinpoint companies with bullish sentiment is by looking at company insider buying trends. After all, company insiders [...]

Still Bullish on BioMarin, Lexicon Pharma

Still Bullish on BioMarin, Lexicon Pharma

TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

Lexicon Pharma: Blockbuster Potential From A Diabetes Drug

Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.

Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Lexicon Pharmaceuticals' CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

Lexicon Pharmaceuticals' CEO Presents at Morgan Stanley Healthcare Conference (Transcript)

Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)

Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)

Lexicon's CEO Presents at Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)

Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Lexicon Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

There isn't a day that goes by on Wall Street that certain stocks trading near or under $10 a share don't experience massive spikes higher.

Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data From Phase 2b Trial (Transcript)

Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data From Phase 2b Trial (Transcript)

Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data from Phase 2b Trial (Transcript)

22 Biopharma Stocks With Breakout Potential in 2012

22 Biopharma Stocks With Breakout Potential in 2012

TheStreet's Adam Feuerstein has compiled a list of drugs with crucial, stock-moving clinical trial catalysts for the remainder of 2012.

TheStreet Quant Rating: D- (Sell)